AnaptysBio, Inc. Common Stock (ANAB)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 104
- Market Cap
- $1.6B
About AnaptysBio, Inc. Common Stock
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
SentiSense also tracks daily options readings for AnaptysBio, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
AnaptysBio, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.